Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentaethylene Glycol SCHEMBL1115918 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Tetraethylene Glycol SCHEMBL8446693 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL9056861 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Tetraethylene Glycol SCHEMBL5481290 | 0.87 | MEN1 (0.79) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL6267958 | 0.87 | MEN1 (0.79) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL3701476 | 0.87 | MEN1 (0.79) | MEN1KMT2ATSHRMAPK1THRB | |
| Tetraethylene Glycol SCHEMBL16424033 | 0.87 | MEN1 (0.92) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL844249 | 0.84 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL30688068 | 0.84 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL1115916 | 0.84 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102380098-B | Combination therapy for the treatment of ocular neovascular disorders | OPHTHOTECH CORP | 2015-07-22 | — | — | CN | claimed |
| CN-102813923-B | Combination therapy for the treatment of ocular neovascular disorders | OPHTHOTECH CORP | 2015-04-01 | — | — | CN | claimed |
| CN-1934255-B | Combination therapy for the treatment of ocular neovascular diseases | OSI EYETECH INC | 2012-07-11 | — | — | CN | claimed |
| CN-102380098-A | Combination therapy for the treatment of ocular neovascular disorders | EYETECH PHARMACEUTICALS INC | 2012-03-21 | — | — | CN | claimed |
| US-7879993-B2 | Covalently linking PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex; diagnostic and therapeutic agent; improving pharmacokinetic properties | GILEAD SCIENCES, INC. (US) | 2011-02-01 | — | — | US | claimed |
| US-20080207883-A1 | Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes | GILEAD SCIENCES, INC. (US) | 2008-08-28 | — | — | US | claimed |
| CN-122029282-A | Novel aptamers to EphA2 (hepaplatin receptor 2 a) | 阿普塔德尔治疗公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250289957-A1 | POLYMERIC TANDEM DYES WITH LINKER GROUPS | SONY GROUP CORP (JP) | 2025-09-18 | — | — | US | disclosed |
| US-20250243250-A1 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | UNIV AUTÒNOMA DE BARCELONA UAB (ES) | 2025-07-31 | — | — | US | disclosed |
| US-12359071-B2 | Polymeric tandem dyes with linker groups | Sony Group Corporation (JP) | 2025-07-15 | — | — | US | disclosed |
| US-20250188455-A1 | LIPOPHILIC OLIGONUCLEOTIDE CONJUGATES | VANDERBILT UNIVERSITY | 2025-06-12 | — | — | US | disclosed |
| US-12319817-B2 | Polymeric tandem dyes with linker groups | Sony Group Corporation (JP) | 2025-06-03 | — | — | US | disclosed |
| US-12275851-B2 | Polymeric tandem dyes with linker groups | Sony Group Corporation (JP) | 2025-04-15 | — | — | US | disclosed |
| US-6306643-B1 | NUCLEOTIDE SEQUENCE SUPPORT; FOR USE IN MONITORING GENE EXPRESSION; FOR USE IN LINKAGE AND SEQUENCE ANALYSIS | AFFYMETRIX, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1108062-A1 | USE OF POOLED PROBES IN GENETIC ANALYSIS | Affymetrix, Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
| US-6229002-B1 | COMPLEX OF NUCLEIC ACID WHICH BINDS TO PLATELET DERIVED GROWTH FACTOR AND NONIMMUNOGENIC, HIGH MOLECULAR WEIGHT COMPOUND; FOR TARGETED DIAGNOSTIC AND THERAPY; ANTICARCINOGENIC AGENTS; CARDIOVASCULAR DISORDERS; KIDNEY DISEASE | NEXSTAR PHARMACEUTICLAS, INC. | 2001-05-08 | — | — | US | disclosed |
| WO-2000011223-A9 | USE OF POOLED PROBES IN GENETIC ANALYSIS | AFFYMETRIX INC (US) | 2001-04-12 | — | — | WO | disclosed |
| EP-1042348-A1 | PLATELET DERIVED GROWTH FACTOR (PDGF) NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000011223-A1 | USE OF POOLED PROBES IN GENETIC ANALYSIS | AFFYMETRIX, INC. (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999031119-A1 | PLATELET DERIVED GROWTH FACTOR (PDGF) NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12359071-B2 | Polymeric tandem dyes with linker groups | CHRM1, IK, TMT1A | MEN1 552/4885KMT2A 1968/4885TSHR 644/4885 |
| US-20080207883-A1 | Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes | PDGFA, PDGFRA, PDGFRB | MEN1 3941/4885KMT2A 2936/4885TSHR 2373/4885 |
| US-20250289957-A1 | POLYMERIC TANDEM DYES WITH LINKER GROUPS | CHRM1, IK, TMT1A | MEN1 552/4885KMT2A 1968/4885TSHR 644/4885 |
| US-12319817-B2 | Polymeric tandem dyes with linker groups | CHRM1, MTCL3, TMT1A | MEN1 424/4885KMT2A 2441/4885TSHR 409/4885 |
| US-12275851-B2 | Polymeric tandem dyes with linker groups | CHRM1, MTCL3, TMT1A | MEN1 434/4885KMT2A 2444/4885TSHR 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.